Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

About this update from Precision Biosciences, Inc.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000® Index, effective at the close of U.S. equity markets on June 26, 2026, according to the final list of additions published by FTSE Russell. The annual reconstitution of the Russell U.S. indexes ranks eligible U.S. stocks by total market capitalization. Membership in the Russell 2000® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization-based rules. The newly reconstituted Russell U.S. Indexes are expected to commence trading at the market open on Monday, June 29, 2026. "Being added to the Russell 2000 Index broadens our visibility with institutional investors at a pivotal time for Precision BioSciences," said Alex Kelly, Chief Financial Officer of Precision BioSciences. "We are advancing two wholly owned clinical programs, PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, with a cash runway supporting our operations through 2028." For more information on the Russell indexes reconstitution, visit the FTSE Russell website. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of clinical stage in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com. The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination (removing a genome e.g. viral DNA such as in the Company’s PBGENE-HBV program), and excision (removing a large portion of a defective gene by delivering two ARC...

View stock analysis, news, and events for Precision Biosciences, Inc.